Glaukos Launches Novel Keratoconus Treatment, Expanding Ophthalmology Portfolio
Event summary
- Glaukos launched Epioxa™ HD / Epioxa™, a topical corneal cross-linking therapy for keratoconus, on March 19, 2026.
- Epioxa represents an incision-free alternative to traditional corneal cross-linking, eliminating the need for corneal epithelium removal.
- The therapy is FDA-approved for use in adults and pediatric patients aged 13 and older, utilizing enriched oxygen and light.
- Glaukos plans to increase investments in patient awareness, education, and access programs to address underdiagnosis and undertreatment of keratoconus.
The big picture
Glaukos's entry into this niche market with a differentiated product positions the company to capture a significant share of the keratoconus treatment landscape, which has historically been underserved. The company's focus on patient access programs signals a broader shift towards value-based care and addressing unmet needs within rare disease communities. This launch also reinforces Glaukos's strategy of expanding its portfolio beyond glaucoma treatments into related ophthalmic disorders.
What we're watching
- Market Adoption
- The success of Epioxa will hinge on physician adoption and patient acceptance of the epithelium-on approach, which could be slower if concerns about efficacy or safety arise.
- Reimbursement
- How insurance providers reimburse for Epioxa, given its novel approach and potential cost savings compared to traditional methods, will significantly impact its market penetration.
- Competitive Response
- Existing players in the corneal cross-linking space may accelerate development of competing therapies or strategies to counter Epioxa's advantages, potentially eroding Glaukos's market share.
Related topics